Alejandro Gabutti, MD

Articles by Alejandro Gabutti, MD

How to Radiologically Assess and Follow Response After Treatment of Hepatocellular Carcinoma

ByAlejandro Gabutti, MD,Tommaso Cascella, MD

April 21st 2021

A thought-provoking installment of Clinical Quandaries is presented by Alejandro Gabutti, MD; and Tommaso Cascella, MD, of a 36-year-old patient with hepatitis C virus-related cirrhosis and a subsequent diagnosis of hepatocellular carcinoma.

Hepatocellular Carcinoma Recurrence After Liver Transplantation

ByAlejandro Gabutti, MD,Sherrie Bhoori, MD,Tommaso Cascella, MD,Marco Bongini, MD

March 19th 2020

The case of a 64-year-old white woman with hepatitis C virus infection-related well-compensated cirrhosis with hepatocellular carcinoma recuurence.

What Are Treatment Options After Progression in PDL-1–Positive Metastatic Lung Adenocarcinoma after Chemo/IO?

ByYuly A. Remolina-Bonilla, MD,Raul R. Trejo-Rosales, MD,Bruno Saldivar-Oviedo,Alejandro Gabutti, MD,María T. Bourlon, MD, MSc, FASCO

August 23rd 2019

What is the best treatment option after progression to chemotherapy/immunotherapy (chemo/IO) as first-line treatment for PD-L1–positive lung adenocarcinoma with no sensitizing mutations?

Diffuse Hepatic Infiltration by Metastatic Melanoma

ByHugo E. Velázquez, MD,Francisco J. Castro-Alonso, MD,Christianne Bourlon, MD, MS,Alejandro Gabutti, MD,Cecilia Gallegos, MD,María T. Bourlon, MD, MSc, FASCO

July 16th 2019

Melanoma of the skin is the 19th most common malignant neoplasm worldwide, with 287,723 new cases estimated for 2018 and metastatic melanoma accounting for 4% of all new cases. In recent years, the prognosis of this stage has undergone a dramatic transformation with the advent of immunotherapy and BRAF/MEK targeted therapy.